RGNX Sura-vec: 60% DRSS at 3 Years in Diabetic Retinopathy

REGENXBIO (RGNX) reported that its one-time gene therapy sura-vec produced durable improvements in diabetic retinopathy at three years, a signal that a single injection could replace a lifetime of eye injections. The data were presented September 24 at the Retina Society’s 59th annual meeting.

In long-term follow-up from the Phase 2 ALTITUDE trial, 60% of participants who received the highest dose (6 of 10) achieved a two-step-or-more improvement on the Diabetic Retinopathy Severity Scale three years after a single in-office suprachoroidal injection. None needed additional diabetic retinopathy treatment, and none had vision-threatening events. Three of four patients who showed a one-step improvement at year one progressed to the two-step bar by year three. Across 17 patients, there was no intraocular inflammation and no new safety signal with short-course prophylactic topical steroids.

The drug, formally surabgene lomparvovec (ABBV-RGX-314), uses REGENXBIO’s NAV AAV8 vector to deliver a gene encoding an anti-VEGF antibody fragment, the same target as injected drugs like Eylea and Lucentis, so the eye continuously produces its own blocker after a single treatment. Diabetic retinopathy is the leading cause of vision loss in working-age adults and affects nearly 10 million people in the US. Today, non-proliferative disease is managed with “watchful waiting” or repeat anti-VEGF injections. The wet AMD indication, where sura-vec is also in late-stage trials, affects roughly 2 million Americans. Three years is a meaningful durability benchmark, because the field’s core question is whether a single gene therapy dose holds up or fades and forces patients back to injections.

REGENXBIO closed at $7.40. The readout is a needed positive for a company hit by an August clinical hold on its RGX-121 Hunter syndrome program. The dose used here is advancing in the Phase 2b/3 NAAVIGATE trial, and AbbVie, which co-develops the program, has already paid a $100 million milestone tied to dosing the first NAAVIGATE patient. REGENXBIO has also guided to a Duchenne BLA in the third quarter and a wet AMD Phase 3 topline in the fourth.

The caveat is the sample size. The 60% figure rests on six patients, there was no comparator anti-VEGF arm in this readout, and a registrational result is years away. Still, the three-year durability, with no inflammation and no rescue injections, extends sura-vec’s thesis beyond wet AMD into a much larger diabetic retinopathy market.

What to watch next: the NAAVIGATE enrollment pace and the wet AMD Phase 3 topline REGENXBIO has guided to the fourth quarter. Read the NAAVIGATE $100M milestone, the sura-vec wet AMD primer, or the REGENXBIO announcement

What It Means for the Trade

The trade here is a cheap gene-therapy option with dated catalysts. RGNX closed at $7.40, and the stock needs wins: an August clinical hold on the RGX-121 Hunter syndrome program set the narrative back, so a clean three-year durability readout is less a stock mover than a thesis-saver. The near-term catalysts are visible on a quarter-by-quarter clock — AbbVie’s $100 million milestone is already paid for dosing the first NAAVIGATE patient, a Duchenne BLA is guided for the third quarter, and the wet AMD Phase 3 topline lands in the fourth. The diabetic retinopathy data is the long-dated optionality: nearly 10 million US patients versus roughly 2 million for wet AMD, and a one-time suprachoroidal injection replacing a lifetime of anti-VEGF shots is the kind of pharmacoeconomic argument payers actually listen to. The three-year durability is what makes it credible — six of ten high-dose patients at a two-step DRSS improvement with zero rescue injections is the exact metric this field has been waiting on. Treat this as a story of optionality on a weakened stock, with the wet AMD topline as the nearest hard event.

Mechanism and Market Context

Sura-vec’s design is the differentiator: NAV AAV8 delivers a gene encoding an anti-VEGF antibody fragment, so the eye manufactures its own blocker continuously after one in-office suprachoroidal injection. That is the same target as Eylea and Lucentis, but the delivery turns a chronic injection burden into a one-time procedure. The durability trend inside the data is quietly the most important number — three of four patients who showed a one-step DRSS improvement at year one progressed to the two-step bar by year three, which argues the effect builds rather than fades. Short-course prophylactic topical steroids held inflammation at zero across 17 patients, answering the field’s main safety worry.

Risks and What Could Go Wrong

1. The 60% figure rests on six patients in a Phase 2 long-term follow-up — hypothesis-grade, not registrational.
2. There was no comparator anti-VEGF arm in this readout.
3. A registrational diabetic retinopathy result is years away, and the clinical hold on RGX-121 shows program risk is real across the pipeline.
4. Gene-therapy durability can fade past five years, and the field has been burned before.